Modality
mAb
MOA
GLP-1/GIP
Target
JAK2
Pathway
DDR
MCL
Development Pipeline
Preclinical
~Dec 2016
→ ~Mar 2018
Phase 1
Jun 2018
→ Dec 2029
Phase 1Current
NCT08069068
2,727 pts·MCL
2022-01→2029-08·Recruiting
NCT03278887
2,674 pts·MCL
2018-06→2029-12·Active
5,401 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2029-08-133.4y awayPh2 Data· MCL
2029-12-123.7y awayPh2 Data· MCL
Trial Timeline
Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q4
P1/2
Active
P1/2
Recruit…
Catalysts
Ph2 Data
2029-08-13 · 3.4y away
MCL
Ph2 Data
2029-12-12 · 3.7y away
MCL
RecruitingActive|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08069068 | Phase 1/2 | MCL | Recruiting | 2727 | 6MWD |
| NCT03278887 | Phase 1/2 | MCL | Active | 2674 | Mayo |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Zanuderotide | Johnson & Johnson | Phase 2/3 | TIGIT | |
| JNJ-8168 | Johnson & Johnson | Phase 2/3 | FLT3 | |
| AZN-5171 | AstraZeneca | Approved | GLP-1R | |
| GMA-5010 | Genmab | Phase 3 | JAK2 | |
| Pemiinavolisib | Sarepta | NDA/BLA | CD47 | |
| Teravorutinib | Illumina | Phase 2 | JAK2 | |
| AXS-4984 | Axsome | Preclinical | JAK2 | |
| Capirapivir | TG Therapeutics | Approved | JAK2 | |
| Zenorelsin | Disc Medicine | NDA/BLA | JAK2 | |
| IRO-8712 | Disc Medicine | Preclinical | JAK2 |